No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
Top Premarket Gainers
12 Health Care Stocks Moving In Friday's Pre-Market Session
NASDAQ New 52-Week Highs And Lows
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Express News | Actuate Therapeutics Inc: To Report Topline Data From Phase 2 Trial of Elraglusib in 1H 2025